CN115867533B - 色胺前药 - Google Patents

色胺前药 Download PDF

Info

Publication number
CN115867533B
CN115867533B CN202180046999.1A CN202180046999A CN115867533B CN 115867533 B CN115867533 B CN 115867533B CN 202180046999 A CN202180046999 A CN 202180046999A CN 115867533 B CN115867533 B CN 115867533B
Authority
CN
China
Prior art keywords
compound
depression
drug
tryptamine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180046999.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN115867533A (zh
Inventor
N·布莱森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruian Neuroscience Co
Original Assignee
Canadian Ryan Neuroscience Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canadian Ryan Neuroscience Co filed Critical Canadian Ryan Neuroscience Co
Priority to CN202410898893.XA priority Critical patent/CN119285526A/zh
Priority to CN202410898937.9A priority patent/CN119285527A/zh
Publication of CN115867533A publication Critical patent/CN115867533A/zh
Application granted granted Critical
Publication of CN115867533B publication Critical patent/CN115867533B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180046999.1A 2020-06-30 2021-06-30 色胺前药 Active CN115867533B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410898893.XA CN119285526A (zh) 2020-06-30 2021-06-30 色胺前药
CN202410898937.9A CN119285527A (zh) 2020-06-30 2021-06-30 色胺前药

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063045901P 2020-06-30 2020-06-30
US63/045,901 2020-06-30
US202063109095P 2020-11-03 2020-11-03
US63/109,095 2020-11-03
PCT/CA2021/050907 WO2022000091A1 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410898893.XA Division CN119285526A (zh) 2020-06-30 2021-06-30 色胺前药
CN202410898937.9A Division CN119285527A (zh) 2020-06-30 2021-06-30 色胺前药

Publications (2)

Publication Number Publication Date
CN115867533A CN115867533A (zh) 2023-03-28
CN115867533B true CN115867533B (zh) 2024-07-23

Family

ID=79032374

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180046999.1A Active CN115867533B (zh) 2020-06-30 2021-06-30 色胺前药
CN202410898893.XA Pending CN119285526A (zh) 2020-06-30 2021-06-30 色胺前药
CN202410898937.9A Pending CN119285527A (zh) 2020-06-30 2021-06-30 色胺前药

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410898893.XA Pending CN119285526A (zh) 2020-06-30 2021-06-30 色胺前药
CN202410898937.9A Pending CN119285527A (zh) 2020-06-30 2021-06-30 色胺前药

Country Status (10)

Country Link
US (4) US11292765B2 (https=)
EP (1) EP4172145A4 (https=)
JP (2) JP7702654B2 (https=)
KR (2) KR20250103811A (https=)
CN (3) CN115867533B (https=)
AU (1) AU2021302692A1 (https=)
CA (1) CA3181092A1 (https=)
IL (2) IL299506B2 (https=)
MX (1) MX2022016212A (https=)
WO (1) WO2022000091A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
MX2022009528A (es) 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
CN115867533B (zh) * 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
WO2022040802A1 (en) * 2020-08-26 2022-03-03 Magicmed Industries Inc. Glycosylated psilocybin derivatives and methods of using
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
EP4263504A4 (en) * 2020-12-18 2025-05-14 COMPASS Pathfinder Limited Modified indole alkaloids for therapeutic uses
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
BR112023025599A2 (pt) 2021-06-08 2024-02-20 Entheogenix Biosciences Inc Ativadores de dimetoxifenilalquilamina de receptores de serotonina.
CA3225133A1 (en) 2021-07-07 2023-01-12 Matthew Alexander James Duncton N,n-dimethyltryptamine and related psychedlics and uses thereof
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
WO2023023347A1 (en) * 2021-08-20 2023-02-23 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof
EP4429672A4 (en) 2021-11-12 2025-04-30 Terran Biosciences Inc. PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF
US12404238B2 (en) 2021-12-10 2025-09-02 Caamtech, Inc. Psilocybin derivatives
JP2024546138A (ja) * 2021-12-14 2024-12-17 レユニオン ニューロサイエンス，インコーポレイテッド トリプタミンプロドラッグ
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023133477A1 (en) * 2022-01-06 2023-07-13 Terran Biosciences, Inc. Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250186369A1 (en) * 2022-03-07 2025-06-12 Drexel University Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493542A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc C4-CARBONOTHIOATE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE
AU2022446955A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493544A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE
WO2023201293A2 (en) * 2022-04-13 2023-10-19 Caamtech, Inc. Tryptamine derivatives
CN115521240B (zh) * 2022-06-01 2024-05-28 杭州奥泰生物技术股份有限公司 一种二甲基色胺半抗原和人工抗原及其制备方法与应用
EP4561527A2 (en) * 2022-07-27 2025-06-04 Reconnect Labs AG Highly soluble formulations of harmine
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
CN116283885B (zh) * 2022-12-01 2025-02-14 杭州奥泰生物技术股份有限公司 一种帕罗西汀半抗原和人工抗原及其制备方法与应用
JP2026501775A (ja) * 2023-01-05 2026-01-16 リユニオン・ニューロサイエンス、インコーポレイテッド トリプタミンプロドラッグの薬物動態の改善
WO2024178051A2 (en) * 2023-02-22 2024-08-29 Caamtech, Inc. Tryptamine derivatives
EP4704822A1 (en) 2023-05-01 2026-03-11 ATAI Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025099725A1 (en) * 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
WO2025238416A1 (en) * 2024-05-16 2025-11-20 Mindset Pharma Inc. Indole derivatives, uses and compositions thereof
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate
WO2026024591A1 (en) * 2024-07-22 2026-01-29 Reunion Neuroscience, Inc. Tryptamine prodrug solid forms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) * 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
NL243249A (https=) 1958-09-12
CH373381A (de) 1959-07-13 1963-11-30 Sandoz Ag Verfahren zur Herstellung neuer basischer Indol-Derivate
CH386422A (de) 1960-03-30 1965-01-15 Sandoz Ag Verfahren zur Herstellung neuer Ester der Indol-Reihe
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2147991A1 (en) * 1993-09-01 1995-03-09 Richard A. Glennon Tryptamine analogs with 5-ht1d selectivity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU2005300045A1 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
CN115867533B (zh) * 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
EP4263504A4 (en) * 2020-12-18 2025-05-14 COMPASS Pathfinder Limited Modified indole alkaloids for therapeutic uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS RN 902412-24-2、33598-45-7、2519519-21-0;REGISTRY;STN International;1-3 *

Also Published As

Publication number Publication date
JP7702654B2 (ja) 2025-07-04
CA3181092A1 (en) 2022-01-06
US20210403425A1 (en) 2021-12-30
WO2022000091A1 (en) 2022-01-06
MX2022016212A (es) 2023-03-02
CN119285526A (zh) 2025-01-10
EP4172145A4 (en) 2024-08-21
CN115867533A (zh) 2023-03-28
JP2025143280A (ja) 2025-10-01
IL299506A (en) 2023-02-01
IL299506B1 (en) 2025-06-01
KR20250103811A (ko) 2025-07-07
IL299506B2 (en) 2025-10-01
EP4172145A1 (en) 2023-05-03
KR102829078B1 (ko) 2025-07-04
US20220177427A1 (en) 2022-06-09
US11292765B2 (en) 2022-04-05
AU2021302692A1 (en) 2023-01-19
IL320601A (en) 2025-07-01
US20250129023A1 (en) 2025-04-24
US20250382267A1 (en) 2025-12-18
KR20230028543A (ko) 2023-02-28
CN119285527A (zh) 2025-01-10
JP2023531311A (ja) 2023-07-21

Similar Documents

Publication Publication Date Title
CN115867533B (zh) 色胺前药
CN118679146A (zh) 色胺前药
EA007008B1 (ru) Триамидзамещённые индолы, бензофураны и бензотиофены в качестве ингибиторов микросомального белка, переносящего триглицериды, (мтр) и/или ингибиторов секреции аполипопротеина в (аро в)
US10676438B2 (en) KCNQ2-5 channel activator
WO2005016326A2 (en) Analogs of thalidomide as potential angiogenesis inhibitors
TW201021798A (en) Amide acetate derivative having inhibitory activity on endothelial lipase
WO1999020620A1 (en) Isoquinoline derivative and drug
WO2016159577A2 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
WO2018133670A1 (zh) 丁苯酞-替米沙坦杂合物及其制备方法和用途
RU2742770C1 (ru) Производное индола и формамида, способ его получения и применение в медицине
JPWO2005021486A1 (ja) エステル誘導体及びその医薬用途
CA3075324A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
HK40114252A (zh) 色胺前药
HK40114605A (zh) 色胺前药
HK40091294A (zh) 色胺前药
HK40091294B (zh) 色胺前药
HK40114112A (zh) 色胺前药
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
JPWO2013018685A1 (ja) ラクタム誘導体及びその医薬用途
CN110256461A (zh) 稠杂嘧啶衍生物及其制备方法和应用
EA047746B1 (ru) Конденсированные бициклические стимуляторы sgc

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40091294

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20241218

Address after: new jersey

Patentee after: Ruian Neuroscience Co.

Country or region after: U.S.A.

Address before: Ontario, Canada

Patentee before: Canadian Ryan Neuroscience Co.

Country or region before: Canada